Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing novel fatty acid synthase (FASN) inhibitors to address metabolic and fibrotic disorders linked to the overproduction of palmitate. Its lead product candidate, denifanstat, is an oral FASN inhibitor aimed at treating conditions such as acne and metabolic dysfunction-associated steatohepatitis (MASH). The company operates in the therapeutic areas of dermatology, metabolic disease, and oncology, with plans to advance denifanstat into Phase 3 trials for moderate to severe acne and MASH.
- Website
- sagimet.com
- Issuer profile
- All listings